ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
Abivax S.A.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$87.49−0.64 (-0.73%)
Close on Oct 19, 2026
Share price
−$5.24 (−5.65%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- EPS, diluted
- -4.83 EUR
- Free cash flow
- -€197.27M
- Diluted shares
- 80M
Valuation needs the share price. It fills in once daily prices are connected and converted from EUR.
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, EUR
Operating income
-€292.70M
EPS, diluted
–
Free cash flow
-€197.27M
Reported periodTrailing twelve months